RxDoctor Payments Data

George Schultz, DO

Internal Medicine · Medford, ORNPI 1235225129

Payments from drug & device makers

$353in general payments, 2019–2025

Across 25 payments — averaging $14.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$214
  • Tactile Systems Technology Inc$52
  • AbbVie$36
  • AstraZeneca$32
  • Merck$20

What the payments were for

  • Food & beverage$30185%
  • Education$5215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead17$214
Tactile Systems Technology Inc3$52
AbbVie2$36
AstraZeneca2$32
Merck1$20

How this compares

$353 in reported general payments places this provider in the 85th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$216,154
Medicare patients
368
Services billed
5,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala230$898,878
TriumeqAbacavir/Dolutegravir/Lamivudi128$489,316
DovatoDolutegravir Sodium/Lamivudine123$386,157
GenvoyaElviteg/Cob/Emtri/Tenof Alafen41$159,305
DescovyEmtricitabine/Tenofov Alafenam59$143,995
OdefseyEmtricitab/Rilpiviri/Tenof Ala36$126,921
IsentressRaltegravir Potassium53$102,599
JulucaDolutegravir/Rilpivirine30$102,172
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf16$98,954
OzempicSemaglutide101$98,769
TivicayDolutegravir Sodium42$93,638
EliquisApixaban87$75,468
PrezcobixDarunavir/Cobicistat21$69,220
XareltoRivaroxaban46$57,684
JardianceEmpagliflozin76$51,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$214$1,202,177330 claims
MerckIsentress, Isentress Hd$20$126,17365 claims
AbbVieCreon, Linzess, Savella$36$38,91940 claims
AstraZenecaBreztri Aerosphere$32$6,86511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →